A health condition index for assessing disease progression

ABSTRACT

Introduction

Currently immunotherapy is considered a cutting edge pharmaceutical treatment for non-small cell lung cancer. Tumor profile plays a crucial role in identifying the correct patient group.

Methods

Therefore, initial biopsies and re-biopsies are necessary in order to identify the expression of programmed death-ligand-1.

Results

This information is crucial and therefore all future immunotherapy studies have to be built upon a specific statistical model which associates the tumor profile and tumor profile expression along with treatment efficiency.

Discussion

We present a novel statistical methodology for future immunotherapy studies of non-small cell lung cancer.

KEYWORDS:

• Lung cancer
• re-biopsy
• treatment
• nsclc

Declaration of Interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/17476348.2022.2119132

Additional information

Funding

This paper was not funded.